Emcure Pharmaceuticals Receives Two FDA Observations at Kurkumbh Facility

Emcure Pharmaceuticals today announced that the US FDA inspected its API manufacturing facility at Kurkumbh, Pune from February 19-25, 2025. The inspection ended with two observations in Form 483. The company is working on these observations and will reply to the FDA within the given time frame. This audit comes after earlier regulatory setbacks, such as a 2019 warning letter to the firm's Hinjwadi facility. Emcure, a pharmaceutical firm with international presence, continues to insist on good quality and regulatory standards. The stock market response to this piece of information remains to be known, as the day's trading has not yet begun.

 

Source: Emcure Pharmaceuticals Limited, National Stock Exchange of India